{"id":"bnt327-equivalent-q3w-dose","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, swelling, or itching at the injection site"}]},"_chembl":{"chemblId":"CHEMBL664","moleculeType":"Small molecule","molecularWeight":"176.22"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This vaccine works by introducing a piece of the SARS-CoV-2 virus's genetic material, called messenger RNA (mRNA), into cells. The cells then use this mRNA to produce a piece of the virus's spike protein, which is recognized by the immune system as foreign and triggers an immune response. This immune response helps to protect against future infections with SARS-CoV-2.","oneSentence":"BNT327 is a COVID-19 vaccine candidate that uses a modified mRNA molecule to instruct cells to produce a piece of the SARS-CoQV-2 virus, eliciting an immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:20:08.499Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention"}]},"trialDetails":[{"nctId":"NCT06449222","phase":"PHASE2","title":"Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2024-08-26","conditions":"Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers","enrollment":83}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BNT327 Equivalent Q3W Dose","genericName":"BNT327 Equivalent Q3W Dose","companyName":"BioNTech SE","companyId":"biontech-se","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BNT327 is a small molecule investigational therapy for breast cancer, specifically studied in conditions such as locally advanced breast cancer, triple negative breast cancer, and metastatic triple negative breast cancers. BNT327 is administered in combination with chemotherapy, including Nab-placlitaxel, as part of a Phase II clinical trial (NCT06449222) to evaluate its safety and preliminary effectiveness.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}